CTKBCytek Biosciences, Inc.

$553M

Q2 2024 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$47M-6.2% YoY

Gross Profit

$25M54.6% margin

Operating Income

-$9M-18.3% margin

Net Income

-$10M-22.4% margin

EPS (Diluted)

$-0.08

QoQ Revenue Growth

+3.9%

Cash Flow

Operating Cash Flow

$6M

Free Cash Flow

$5M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$484M

Total Liabilities

$95M

Stockholders' Equity

$389M

Cash & Equivalents

$178M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$47M	$50M	-6.2%
Gross Profit	$25M	$28M	-9.7%
Operating Income	-$9M	-$9M	+6.6%
Net Income	-$10M	-$4M	-137.8%

Revenue Segments

Service

$37M52%

Product

$35M48%

Geographic Segments

UNITED STATES

$22M48%

EMEA

$14M30%

Asia Pacific

$9M19%

Other

$1M3%

CTKB Q2 2024 Earnings — Cytek Biosciences, Inc. Revenue & Financial Results | Market Cap Arena